Nektar Therapeutics announced on April 21, 2026, that it has entered an agreement for an underwritten offering of 3,532,609 shares of common stock at $92.00 per share, expecting to raise approximately $350.9 million. The offering is set to close on April 23, 2026, with an additional option for underwriters to purchase 529,891 shares.